section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Reflects combined therapy with corticosteroids and cyclosporine

CV: edema, hypotension, pericardial effusion.

Derm: acne, rash, thrombocytopenic purpura.

F and E: hypokalemia.

Endo: hyperglycemia.

GI: ascites, hepatotoxicity.

GU: amenorrhea, infertility (males), menorrhagia, ovarian cysts, renal impairment.

Hemat: leukopenia, thrombocytopenia, anemia.

Metab: hypercholesterolemia, hypertriglyceridemia.

MS: arthralgias.

Neuro: tremor , PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML), insomnia.

Resp: interstitial lung disease, pulmonary hypertension.

Misc: ANGIOEDEMA, INFECTION (INCLUDING ACTIVATION OF LATENT VIRAL INFECTIONS SUCH AS BK VIRUS-ASSOCIATED NEPHROPATHY AND CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA [CDAD]), wound healing, lymphocele, lymphoma.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Availability

(Generic available)

Route/Dosage

see Calculator

Kidney Transplantation

Hepatic Impairment

Lymphangioleiomyomatosis

Hepatic Impairment

US Brand Names

Rapamune

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: Immunosuppressant agents

Pharmacokinetics

Absorption: Rapidly absorbed following oral administration (14% bioavailability).

Distribution: Concentrates in erythrocytes; distributes to heart, intestines, kidneys, liver, lungs, muscle, spleen, and testes in high concentrations.

Protein Binding: 92%.

Metabolism/Excretion: Extensively metabolized (some metabolism by P450 3A4 system); 91% excreted in feces.

Half-life: 62 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POrapid1–2 hr24 hr

Patient/Family Teaching

Pronunciation

sir-OH-li-mus audio

Code

NDC Code*